^
    Back
    Association details:
    Biomarker:TP53 mutation + TTN mutation
    Cancer:Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Comb Chem High Throughput Screen
    Title:

    Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma

    Published date:
    10/31/2023
    Excerpt:
    The LUSC patients with TP53 and TTN co-mutation had higher TMB levels and better response to immunotherapy. The TP53 and TTN co-mutation is a promising novel biomarker to assist LUSC immunotherapy evaluation.
    DOI:
    10.2174/0113862073246841230922052004